Longevity & AgingLysoway Launches First Human Trial of Brain-Penetrating Drug to Tackle Alzheimer's and Parkinson's
Lysoway Therapeutics has dosed its first human participant in a Phase 1 trial of LW-1017, a new oral drug targeting the root causes of Alzheimer's and Parkinson's disease. The drug works by activating a protein called TRPML1, which helps restore the brain's internal waste-clearing system — a process called autophagy. When this cellular cleanup breaks down, toxic protein buildup follows, driving neurodegeneration. LW-1017 was engineered to actually reach the brain after oral dosing, overcoming a major barrier that has derailed many previous attempts at similar therapies. The trial, underway in Melbourne, Australia, will first test safety and how the drug behaves in the body across healthy volunteers before moving toward disease populations.
